The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

This is a preview. Log in through your library . Abstract Antigen-specific therapies hold promise for treating autoimmune diseases such as multiple sclerosis while avoiding the deleterious side ...

Journals Flag Concerns in 36 Papers by Nutrition Researchers Journals have flagged more than 36 articles by a team of authors in Iran for concern over the integrity of their data since questions were ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis No drugs are currently approved to treat this type of MS WEDNESDAY, April 9, 2025 (HealthDay ...

Differences in the complexity of the EEG signal (yellow and red colors) in a specific brain area between the group with advanced multiple sclerosis and the control group, and multifractal spectra ...

AUGS Overactive Bladder Symptoms in Patients With Multiple Sclerosis Patients with multiple sclerosis have significant rates of overactive bladder symptoms, yet they are not being evaluated or treated ...

While recent therapies have the potential to stall or delay the progression of multiple sclerosis, a new study shows that young Black and Hispanic women fare worse than young white women. Minority ...

Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...

Multiple Sclerosis Society of India (MSSI) – Bengaluru Chapter, in collaboration with the Rotary Action Group Against Multiple Sclerosis (RAGAMS), hosted an awareness and advocacy programme titled ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...